A New Hope in Alzheimer's Treatment; Lecanemab
Zainab Zaki Abdulkarim Alkhamis, Sofia Ahmed Alkhatibi Alfalasi
International Neuropsychiatric Disease Journal · pp. 40–45 · Published 6 Mar 2023
10.9734/indj/2023/v19i1365Abstract
Lecanemab's apparent effectiveness follows years of disillusionment with earlier, comparable medications that were meant to delay or stop the course of Alzheimer's disease. It contains monoclonal antibodies that were created in laboratories with the goal of purging the brain of a material called as beta-amyloid, exactly like a lot of those other medicines. People with Alzheimer's disease tend to have an accumulation of beta-amyloid in their brains, which leads to the development of the sticky plaques that have come to be associated with the condition. As a result of this, the objective of his research paper is to investigate background information about the drug lecanemab. In addition to this, the study offers information regarding the approval procedure for lecanemab, the drug's mode of action, and, lastly, the most recent discoveries.
Cited by 2
Zaib Un Nisa Mughal, Bisma Ahmed, Fatima Amin · Annals of Neurosciences · 2023
Nandhini Jayaprakash, Karthikeyan Elumalai · Chronic Diseases and Translational Medicine · 2024
Related research
- Phamrmacoligical Therapies for COVID-19: A Comprehensive Review from 2022 Updated Nih, IDSA and ICMR Guidelines — shares topic coverage
- Optimizing the Aggregation Propensity of Therapeutic Monoclonal Antibodies against Cancer and Autoimmune Diseases: A Computational Study — shares topic coverage
- Biopharmaceuticals: New yet Natural — shares topic coverage
- New Monoclonal Antibodies to Human IgA: Obtaining and Study of Biological Properties — shares topic coverage
- Downregulation of Gap Junctions in Astrocytes by Monoclonal Antibodies against the Second Extracellular Loop of Connexin-43 — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
2
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.